Skip to main content
. 2004 Apr 15;10(8):1191–1197. doi: 10.3748/wjg.v10.i8.1191

Figure 6.

Figure 6

Survival time of sarcoma-bearing mice. Twenty-five mice were randomly divided into 5 groups: no treatment, rAAV-LacZ alone, rAAV-LacZ plus etoposide, rAAV-endostatin alone, or rAAV-endostatin plus etoposide. The tu-mor-bearing mice treated with rAAV-endostatin in combina-tion with etoposide had a significantly longer survival than those in other groups (P < 0.05).